Cann Group Ltd - Asset Resilience Ratio
Cann Group Ltd (CAN) has an Asset Resilience Ratio of 1.72% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Cann Group Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Cann Group Ltd's Asset Resilience Ratio has changed over time. See CAN net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Cann Group Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cann Group Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$955.00K | 1.72% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$955.00K | 1.72% |
Asset Resilience Insights
- Limited Liquidity: Cann Group Ltd maintains only 1.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Cann Group Ltd Industry Peers by Asset Resilience Ratio
Compare Cann Group Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Hainan Haiyao Co Ltd
SHE:000566 |
Drug Manufacturers - Specialty & Generic | 3.27% |
|
Shanxi Zhendong Pharmaceutical
SHE:300158 |
Drug Manufacturers - Specialty & Generic | 10.74% |
Annual Asset Resilience Ratio for Cann Group Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Cann Group Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.01% | AU$10.00K ≈ $7.08K |
AU$78.79 Million ≈ $55.75 Million |
-1.76pp |
| 2024-06-30 | 1.77% | AU$1.64 Million ≈ $1.16 Million |
AU$92.77 Million ≈ $65.64 Million |
+1.18pp |
| 2023-06-30 | 0.59% | AU$765.00K ≈ $541.29K |
AU$129.47 Million ≈ $91.61 Million |
-0.78pp |
| 2022-06-30 | 1.37% | AU$1.91 Million ≈ $1.35 Million |
AU$139.66 Million ≈ $98.82 Million |
-1.60pp |
| 2021-06-30 | 2.97% | AU$3.02 Million ≈ $2.14 Million |
AU$101.79 Million ≈ $72.02 Million |
+1.04pp |
| 2020-06-30 | 1.92% | AU$1.47 Million ≈ $1.04 Million |
AU$76.40 Million ≈ $54.06 Million |
-54.57pp |
| 2019-06-30 | 56.49% | AU$46.39 Million ≈ $32.82 Million |
AU$82.11 Million ≈ $58.10 Million |
-35.27pp |
| 2018-06-30 | 91.76% | AU$79.65 Million ≈ $56.36 Million |
AU$86.80 Million ≈ $61.42 Million |
+18.03pp |
| 2017-06-30 | 73.73% | AU$11.11 Million ≈ $7.86 Million |
AU$15.07 Million ≈ $10.67 Million |
-- |
| 2016-12-31 | 0.00% | AU$0.00 ≈ $0.00 |
AU$15.89 Million ≈ $11.25 Million |
-- |
About Cann Group Ltd
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.